Vincent A. de Weger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vincent A. de Weger has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Jan H. M. Schellens
Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, the Netherlands; The Netherlands Cancer Institute, Department of Clinical Pharmacology, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands
2 shared publications - Aart Beeker
Department of Medical Oncology, Spaarne Gasthuis , Hoofddorp
1 shared publication Alwin D.R. Huitema
Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publication- Andrew J. Wagner
Dana-Farber Cancer Institute Department of Medical Oncology Boston, MA 02215
1 shared publication - Aniek Bonhof
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University , Utrecht
1 shared publication - Anne M. May
Julius Center for Health Sciences and Primary care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 27 January 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (2)
Effects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study
Background: Patients with incurable gastroesophageal adenocarcinoma have an impaired health-related quality of life (HRQOL). Exercise combined with nutritional support may improve this outcome. Careful evaluation of this supportive care strategy is needed to avoid burdening patients at this vulnerable stage with interventions that may offer no (meaningful) benefit. Therefore, this study aims to investigate the effects of a combined exercise and nutritional intervention on HRQOL in patients with incurable gastroesophageal adenocarcinoma. Methods: RADICES (the effect of exeRcise And Diet on quality of life in patients with Incurable Cancer of Esophagus and Stomach) is a multicenter randomized controlled trial aiming to include 196 patients with incurable gastroesophageal adenocarcinoma. Participants are randomly assigned (1:1) to a patient-tailored intervention or a control group. The intervention group is provided with 2 training sessions per week and biweekly nutritional consultations, delivered by trained physiotherapists and dietitians, during 12 weeks. The control group receives usual care supplemented with general physical activity advice. The primary outcome is the difference in HRQOL between the intervention group and the control group at 12 weeks, accounting for baseline HRQOL, measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–30 summary score. HRQOL is assessed at baseline, 6 weeks, 12 weeks, and every 3 months thereafter up to 1 year. Key secondary outcomes include patient-reported outcomes, cardiorespiratory fitness, dietary intake, disease progression, overall survival, and cost-effectiveness. Adherence and safety are monitored throughout the intervention period. Conclusion: This study will generate evidence on the effectiveness of a patient-tailored combined exercise and nutritional intervention in patients with incurable gastroesophageal adenocarcinoma. If effective for HRQOL, this intervention could be integrated into standard care for patients with incurable gastroesophageal adenocarcinoma. Trial registration: clinicaltrials.gov NCT06138223. Date of trial registration: November 18, 2023 Date and version study protocol: 28-04-2025 version 3.1 Date start recruitment: 19-01-2024
- 27 January 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (2)
Open AccessEffects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study
Background: Patients with incurable gastroesophageal adenocarcinoma have an impaired health-related quality of life (HRQOL). Exercise combined with nutritional support may improve this outcome. Careful evaluation of this supportive care strategy is needed to avoid burdening patients at this vulnerable stage with interventions that may offer no (meaningful) benefit. Therefore, this study aims to investigate the effects of a combined exercise and nutritional intervention on HRQOL in patients with incurable gastroesophageal adenocarcinoma. Methods: RADICES (the effect of exeRcise And Diet on quality of life in patients with Incurable Cancer of Esophagus and Stomach) is a multicenter randomized controlled trial aiming to include 196 patients with incurable gastroesophageal adenocarcinoma. Participants are randomly assigned (1:1) to a patient-tailored intervention or a control group. The intervention group is provided with 2 training sessions per week and biweekly nutritional consultations, delivered by trained physiotherapists and dietitians, during 12 weeks. The control group receives usual care supplemented with general physical activity advice. The primary outcome is the difference in HRQOL between the intervention group and the control group at 12 weeks, accounting for baseline HRQOL, measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–30 summary score. HRQOL is assessed at baseline, 6 weeks, 12 weeks, and every 3 months thereafter up to 1 year. Key secondary outcomes include patient-reported outcomes, cardiorespiratory fitness, dietary intake, disease progression, overall survival, and cost-effectiveness. Adherence and safety are monitored throughout the intervention period. Conclusion: This study will generate evidence on the effectiveness of a patient-tailored combined exercise and nutritional intervention in patients with incurable gastroesophageal adenocarcinoma. If effective for HRQOL, this intervention could be integrated into standard care for patients with incurable gastroesophageal adenocarcinoma. Trial registration: clinicaltrials.gov NCT06138223. Date of trial registration: November 18, 2023 Date and version study protocol: 28-04-2025 version 3.1 Date start recruitment: 19-01-2024
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Breast Cancer
- Vol. 26 (5) , 519-523
Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
De Weger VA, et al. J Breast Cancer. 2023 Aug;26:e38. https://doi.org/10.4048/jbc.2023.26.e38
- 1 January 2023
- Published by XMLink in Journal of Breast Cancer
- Vol. 26 (5) , 519-523
Open AccessSuccessful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
De Weger VA, et al. J Breast Cancer. 2023 Aug;26:e38. https://doi.org/10.4048/jbc.2023.26.e38
- 3 November 2017
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (1) , 73-80
A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors
Dovitinib is an orally available multi tyrosine kinase inhibitor which inhibits VEGFR 1–3, FGFR 1–3, and PDGFR. This study was performed to investigate the potential drug–drug interaction of dovitinib with the CYP1A2 inhibitor fluvoxamine in patients with advanced solid tumors.
- 3 November 2017
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 81 (1) , 73-80
A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors
Dovitinib is an orally available multi tyrosine kinase inhibitor which inhibits VEGFR 1–3, FGFR 1–3, and PDGFR. This study was performed to investigate the potential drug–drug interaction of dovitinib with the CYP1A2 inhibitor fluvoxamine in patients with advanced solid tumors.
- 1 November 2017
- Published by Elsevier in European Journal of Cancer
- Vol. 86, 217-225
A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir
- 1 November 2017
- Published by Elsevier in European Journal of Cancer
- Vol. 86, 217-225
A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir
- 1 May 2017
- Published by Elsevier in European Journal of Cancer
- Vol. 76, 144-151
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
- 1 May 2017
- Published by Elsevier in European Journal of Cancer
- Vol. 76, 144-151
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours